Deals roundup: ISS recommends shareholders should reject $10.9 Biomet deal May 31, 2007 By Holland Johnson
Novacea Soars On Potential $440M Schering-Plough Deal May 31, 2007 By Jennifer Boggs Novacea Inc. found a partner for its late-stage prostate cancer drug, Asentar, licensing product rights to Schering-Plough Corp. in exchange for $60 million up front and the potential for $380 million in milestones down the road. (BioWorld Today)Read More
RSS